Solid Tumor Therapeutics Market Report 2025 (Global Edition)

Global Solid Tumor Therapeutics Market Report 2025 Market Size Split by Type (Sarcomas, Carcinomas), by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), b...

Solid Tumor Therapeutics Market Report Description

We have various report editions of Solid Tumor Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive landscape: Solid Tumor Therapeutics

Businesses spend money on R&D to find and create cutting-edge solid tumor treatments. This entails finding novel targets, carrying out preclinical and clinical research, and requesting regulatory clearances. Pharmaceutical corporations, biotechnology companies, and academic institutions engage in collaborations, partnerships, and licensing agreements that foster innovation and enhance their product portfolios. The sharing of resources, talent, and information is facilitated by these collaborations. Businesses concentrate on growing their market share through mergers and acquisitions, regional growth, and entry into new market niches. Market expansion strategies help companies broaden their product offerings and strengthen their competitive position. Businesses may increase their competitiveness and diversify their product offerings by using market expansion strategies. 

Top Companies Market Share in Solid Tumor Therapeutics Industry: (In no particular order of Rank)

• Hoffmann La Roche
• Johnson& Johnson
• Novartis
• AstraZeneca
• Biogen Idec
• Boehringer Ingelheim
• GlaxoSmithKline
• Eli Lilly
• Kyowa Hakko Kirin
• Abbott Laboratories
• Baxter International
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Market in 2024?

Because of the high incidence of cancer, the large amount of money spent on research and development, and the dominance of industry players, North America is anticipated to occupy a sizable portion of the market under study. Additionally, as per the March 2023 update to the National Institute of Health article, the grants awarded by the US government in 2022 for the study and advancement of lung, colorectal, and ovarian cancers were USD 479 million, USD 346 million, and USD 178 million, respectively. The large expenditure is anticipated to support the region's market expansion by developing cutting-edge solid tumor therapies for these malignancies.
https://www.cancer.gov/news-events/cancer-currents-blog/2023/new-online-march-2023

Which Region is Expanding at the Fastest CAGR?

Europe is expanding at the fastest CAGR in 2024. Germany is expected to support the growth of the solid tumor cancer treatment market due to the growing number of clinical studies being undertaken there, particularly in light of the expansion of the European area. Other factors driving the growth of the solid tumor cancer treatment market include the rapidly expanding number of female patients with breast cancer and the increasing use of targeted medicines to restrict the spread of the disease. Furthermore, the development of cancer therapies has been aided by the significant amounts spent on research and development. In addition, the market has grown as a result of recent mergers, acquisitions, and product releases among the major companies in the industry, as well as advantageous government policies for cancer therapies.

The current report Scope analyzes Solid Tumor Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Solid Tumor Therapeutics Market Analysis

Solid Tumor Therapeutics Market Type Segment Analysis

• Sarcomas
• Carcinomas

The solid tumor cancer treatment market is segmented by type into Sarcomas and Carcinomas. Carcinoma is a prevalent type of solid tumor cancer detected in the diagnosis processEpithelial cells, which line the linings of glands, organs, and skin, create tissue in carcinomas. The market for solid tumor cancer treatments is anticipated to rise in response to the growing number of people suffering from adrenocortical carcinomas. The disease known as adrenal gland carcinoma occurs when a solid tumor forms in the glands that lie behind the kidney. A solid tumor develops in the lymphatic, blood, or bone vessels in sarcomas.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Solid Tumor Therapeutics Industry. Request a Free Sample PDF!

Solid Tumor Therapeutics Market Cancer Type Segment Analysis

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Cervical Cancer

Based on the cancer type the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancer types. Over the forecast period, there will likely be a healthy increase in breast cancer cases. Due to the high incidence of breast cancer and the increasing number of product releases by industry participants, the breast cancer segment is anticipated to develop healthily throughout the projection period. Globally rising rates of breast cancer are predicted to increase demand for cutting-edge solid tumor therapies, spurring market expansion. The government's awareness campaigns to inform the public about early detection and treatment of breast cancer also contribute to the market's growth. Such initiatives are projected to increase the diagnosis, thereby propelling the solid tumor breast cancer therapeutics use during the analysis period.
•    For instance, as per the Canadian Medical Association Journal May 2022 report, around 28.6 thousand new breast cancer cases were diagnosed in Canada in 2022, which accounted for 25% of the total new cancer diagnosed in women in Canada in 2022.
(Source:https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/breast-cancer.html )

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Solid Tumor Therapeutics Drug Type Segment Analysis

Based on the drug type the market is segmented into carboplatin, cisplatin, gemcitabine, paclitaxel, doxorubicin, bevacizumab, erlotinib, sunitinib, everolimus, and other drug types. Among these carboplatin segment dominates the market during the forecast period. Carboplatin is a member of the class of drugs called alkylating agents. It is used to treat ovarian cancer. Carboplatin belongs to a group of drugs called platinum-containing compounds. It functions similarly to cisplatin, an anticancer medication, although it could be more tolerable. The mechanism of action of carboplatin is to either kill or halt the development of cancer cells. For the reasons listed above, the category is anticipated to increase significantly throughout the course of the projection year.
•    For instance, Teva Pharmaceutical Industries Ltd. announced that the U. S. Food and Drug Administration has granted tentative approval for the company's ANDA for Carboplatin Injection, 50 mg, 150 mg, and 450 mg.
(Source:https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2003/Teva-Announces-Tentative-Approval-of-Carboplatin-Injection/default.aspx )

• Carboplatin
• Cisplatin
• Gemcitabine
• Paclitaxel
• Doxorubicin
• Bevacizumab
• Erlotinib
• Sunitinib
• Everolimus

Solid Tumor Therapeutics Treatment Segment Analysis

By treatment, the solid tumor cancer treatment market is segmented into Chemotherapy, Immunotherapy, and Targeted therapy. Chemotherapy holds the largest share of the solid tumor cancer treatment market. Chemotherapy is still a frequently used treatment for solid tumors. It entails using cytotoxic medications to either eradicate or stop the development of cancer cells. The cancer medications are administered by needle through an inserting tube into the body, even though chemotherapy has negative effects. Chemotherapy may occasionally be administered using mouthable medications. Chemotherapy is thought to be the most effective treatment for killing cancer cells that proliferate quickly. 
•    For instance, Researchers at City of Hope, one of the largest cancer research & treatment organizations in the United States, developed targeted chemotherapy which developed cell nuclear antigen (CNA) that appears to annihilate all solid tumors in preclinical research.
(Sourec:https://www.cityofhope.org/city-hope-scientists-develop-targeted-chemotherapy-able-kill-all-solid-tumors-preclinical-research#:~:text=LOS%20ANGELES%20%E2%80%94%20Researchers%20at%20City,PCNA)%2C%20and%20developed%20a%20targeted )

• Chemotherapy
• Immunotherapy
• Targeted therapy

Solid Tumor Therapeutics Route of Administration Segment Analysis

By route of administration, the solid tumor cancer treatment market is segmented into Oral, Parenteral, and Others. Among these oral route of administration will dominate the market. Oral administration involves administering medication or medications orally as a liquid, pill, or capsule. In the early stages of cancer, oncologists advise oral chemotherapy. When administering medication by injection or infusion for the treatment of solid tumor cancer, the parenteral method of delivery is frequently utilized. The market for solid tumor cancer treatments is expanding due to the use of the parenteral mode of administration, which enables the medications to enter the body of the cancer patient swiftly and consistently.
•    For instance, on 6 May 2021, the FDA approved the commencement of endoxifen research for ovarian cancer treatment where a patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of FDA-approved tamoxifen.
(Source:https://www.targetedonc.com/view/fda-okays-initiation-of-endoxifen-study-in-ovarian-cancer)

• Oral
• Parenteral
• Others

Solid Tumor Therapeutics End-User Segment Analysis

By end-users, the solid tumor cancer treatment market is segmented into Hospitals, Research institutes, Homecare, and Others. Hospitals are the fastest growing end-user for the solid tumor cancer treatment market owing to the increasing prevalence of types of cancer. By offering specialized centers for the effective treatment of solid tumor cancer, hospitals are growing. Furthermore, they are thought to be the group that is expanding the fastest, with rising healthcare infrastructure in developing nations like Kenya, Indonesia, India, and Iran, among others. Research institutions also contribute significantly to the solid tumor cancer treatment market expansion by offering cutting-edge medications and technologies that improve healthcare delivery.

• Hospitals
• Research institutes
• Homecare

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion